AstraZeneca's Forxiga (Dapagliflozin) Has Been Approved In China To Reduce The Risk Of Cardiovascular Death, Hospitalization For Heart Failure (HF), Or Urgent HF Visits In Adults With Symptomatic Chronic HF Regardless Of Ejection Fraction Phenotype
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's drug Forxiga (Dapagliflozin) has received approval in China for use in reducing the risk of cardiovascular death, hospitalization for heart failure, or urgent heart failure visits in adults with symptomatic chronic heart failure, regardless of ejection fraction phenotype.
August 18, 2023 | 7:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Forxiga has been approved in China, potentially increasing the company's market share in the country's healthcare sector.
The approval of Forxiga in China is a significant milestone for AstraZeneca, as it opens up a new market for the drug. This could potentially lead to increased sales and revenues for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100